NewEdge Advisors’s Perspective Therapeutics CATX Stock Holding History

NewEdge Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	-$11	–	4007
2025 Q1	$11	Buy	+5	New	+$15	﹤0.01%	3909

Other funds holding CATX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's CATX Position: Q2 2025 in Review

NewEdge Advisors sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 5 shares — an estimated $11 sold.

NewEdge Advisors first reported a position in CATX in Q1 2025 and held it in 1 quarter. The position peaked at $11 in Q1 2025. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

NewEdge Advisors reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 5 Perspective Therapeutics shares in Q2 2025, an estimated $11.
NewEdge Advisors first reported a position in Perspective Therapeutics in Q1 2025 and held it in 1 quarter.
NewEdge Advisors's Perspective Therapeutics position peaked at $11 in Q1 2025.
97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.